A recent paper published in the Journal of Clinical Oncology updated the outcomes of multiple myeloma trials conducted by the Intergroupe Francophone du Myelome, the Southwest Oncology Group, and the University of Arkansas for Medical Sciences.
The update provides a fuller, long-term picture of the advantages of some of the autotransplant regimens being tested. It represents the first international effort at systematically updating previously reported trial results, which had indicated that autotransplantation with high-dose melphalan (Alkeran) therapy significantly extends the survival of multiple myeloma patients.
Autologous stem cell transplantation, or autotransplantation, is a…
The use of thalidomide (Thalomid) in induction and maintenance therapies for multiple myeloma patients receiving a stem cell transplant resulted in better overall response rates but did not significantly improve overall survival, according to a Phase 3 study recently published in the journal Blood.
In their study, researchers randomly assigned 556 patients to receive three cycles of either vincristine (Oncovin), doxorubicin, and dexamethasone [VAD] or thalidomide, doxorubicin (Adriamycin), and dexamethasone (Decadron) [TAD] as induction therapy. All patients received high-dose melphalan (Alkeran) with an autologous stem cell transplant, followed by maintenance therapy with either alpha-interferon for patients…
A recent study published in the Journal of Clinical Oncology determined that patients who achieved very good partial response (VGPR) or better after high-dose chemotherapy and stem cell transplantation experienced significantly longer event-free and overall survival.
“Very good partial response” is one of the terms defined by the International Myeloma Working Group (IMWG) to categorize how patients respond to treatment. According to IMWG criteria (see related Beacon news), patients reach very good partial response when the level of abnormal “M” proteins in their blood decreases by 90 percent.
Previous studies evaluating high-dose chemotherapy…
Dacetuzumab Shows Some Potential For Multiple Myeloma – Results from a Phase 1 clinical trial show that dacetuzumab (SGN-40), an anti-CD40 monoclonal antibody, has some anti-myeloma effects. The best response observed during the trial was stable disease in 20 percent of patients. The study authors found that doses up to 12 mg/kg per week were well tolerated. Most side effects were mild to moderate and included fatigue, headache, nausea, and anemia. The study authors suggest that dacetuzumab may produce better response rates in combination with other myeloma drugs. Two combination trials (one with Revlimid (lenalidomide) and one with Velcade (bortezomib)) are underway. For more information, please see the study in The Haematologica Journal (pdf) and the clinical trial descriptions (dacetuzumab with Revlimid or Velcade) .
Myeloma Awareness Month Teleconference Series – Each Friday during the month of March, the International Myeloma Foundation (IMF) will be hosting a teleconference to raise awareness and provide up-to-date information about multiple myeloma. The teleconferences are scheduled for 7 p.m. EST and will include a 60 minute presentation followed by a 30 minute Q&A. Patients, family members, caregivers, and health care professionals are welcome to join. Please see the IMF Web site for more information.
NCI Designs MGUS/Smoldering Myeloma Study – Researchers from the National Cancer Institute (NCI) are in the process of developing a prospective study with the goal of identifying causes of transformation from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (both asymptomatic, pre-malignant disorders) to multiple myeloma. The study will enroll 350 patients with MGUS or smoldering myeloma in the United States and follow them for up to five years. For more information, please contact the research nurse for this study, Mary Ann Yancey, at (301) 435-9227 or yanceym@mail.nih.gov.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
Patients who do not respond at least partially to treatment with Revlimid (lenalidomide) or thalidomide (Thalomid) prior to a stem cell transplant may have significantly shorter survival times, according to a recent study published in the journal Blood.
Currently, the standard treatment plan involving stem cell transplantation begins with induction therapy, which decreases the number of abnormal cells and proteins in a patient’s bone marrow before collection of stem cells for the transplant. Next, patients undergo high-dose chemotherapy and transplantation, after which, some patients receive consolidation or maintenance therapy.
Past studies have…
News
- The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
- A New Beacon For The Multiple Myeloma Community
- Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
- Swine Flu Vaccinations Recommended For Multiple Myeloma Patients
- Blood Cancers Forum Focuses On Importance Of Clinical Trials
- New Test Helps Predict More Specific Prognoses For Smoldering Myeloma Patients
- Dose-Adjusted Revlimid-Dexamethasone Combination Is Safe And Effective In Multiple Myeloma Patients With Reduced Kidney Function
- Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients
- Beacon NewsFlashes – March 9, 2010
- Study Documents The Impact Of Age At Diagnosis On Myeloma Patient Survival
- Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
- Swine Flu Vaccinations Recommended For Multiple Myeloma Patients
- Study Shows Higher Survival With Revlimid And Low-Dose Dexamethasone Than Revlimid And High-Dose Dexamethasone In Multiple Myeloma Patients
- A New Beacon For The Multiple Myeloma Community
- Study Supports Use Of Kyphoplasty For Multiple Myeloma Patients
Resources
- Defibrotide
- Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
- Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study
- Thought Leader Perspective: Dr. Robert Kyle On Treating Multiple Myeloma
- Papayas, Papain and Multiple Myeloma: A Potential Adjunct Therapy That Requires Further Evaluation
- Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
- Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
- Pomalidomide (Actimid, CC-4047)
- Kidney Failure In Multiple Myeloma Patients - Part 4: Hemodialysis
- Kidney Failure In Multiple Myeloma Patients - Part 1: Overview
Links
Most Recent Comments
- Julie Shilane: Hi Carol, The following Web site lists all of the clinical trials that are currently being conducted...
- Carol Costner: Thank you for the information on MM. My husband has had a stem cell transplant, in November, 2007, and...
- julie: This blog posting has an interesting discussion about the appropriateness of using the word “cure”...
- Malcolm: It always amuses me to hear that standard line that there is not yet enough research to warrant taking the...
- L: GREAT news!!!
Subscribe
News Archives
- ▼2010 (39)
- ▼ March (7)
- New Test Helps Predict More Specific Prognoses For Smoldering Myeloma Patients
- Dose-Adjusted Revlimid-Dexamethasone Combination Is Safe And Effective In Multiple Myeloma Patients With Reduced Kidney Function
- Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients
- Beacon NewsFlashes – March 9, 2010
- Study Documents The Impact Of Age At Diagnosis On Myeloma Patient Survival
- Genetic Risk Factors And Treatment History May Predict Response In Patients With Relapsed/Refractory Myeloma, Study Finds
- International Effort Updates Results From Multiple Myeloma Stem Cell Transplant Trials
- ► February (15)
- Thalidomide As Induction And Maintenance Therapy Improves Response Rates In Multiple Myeloma Patients
- The Top Myeloma Research Of 2009
- Achieving Very Good Partial Response Indicates A Good Prognosis For Multiple Myeloma Patients, Study Finds
- Beacon NewsFlashes – February 18, 2010
- Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence
- Total Therapy Regimen May Be Highly Effective In Newly Diagnosed Myeloma Patients
- Unresponsiveness To Revlimid Or Thalidomide Indicates Poor Response To Stem Cell Transplant, Study Finds
- Revlimid Maintenance Therapy Is Added To Multiple Myeloma Treatment Guidelines
- Revlimid-Cyclophosphamide-Prednisone Combination May Be Highly Effective For Refractory Multiple Myeloma Patients
- Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds
- Bone Formation And Degradation Proteins May Predict Progression Of Multiple Myeloma And Myeloma-Related Bone Disease
- Beacon NewsFlashes – February 5, 2010
- Addition Of Defibrotide To Melphalan-Prednisone-Thalidomide Combination Produces Fewer Side Effects In Multiple Myeloma Patients
- Velcade-Doxil-Dexamethasone Regimen Followed By Post-Transplant Revlimid May Be A Highly Effective Treatment For Newly Diagnosed Myeloma Patients
- Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
- ► January (17)
- Beacon NewsFlashes – January 29, 2009
- Post-Transplant Revlimid Therapy Increases Complete Response Rates In Multiple Myeloma Patients, Study Finds (ASH 2009)
- Despite Side Effects, High-Dose Melphalan Remains The Most Effective Dosage In Preparation For Stem Cell Transplantation
- Velcade Induction and Maintenance Combinations Are Highly Effective In Elderly Multiple Myeloma Patients, Study Finds (ASH 2009)
- Beacon NewsFlashes - January 25, 2010
- Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study
- Statins Reduce Acute Graft-Versus-Host Disease In Allogeneic Stem Cell Transplants, Study Finds
- Study Compares Out-Of-Pocket Expenses For Myeloma Patients Treated With Velcade, Revlimid, Or Thalidomide (ASH 2009)
- Beacon NewsFlashes – January 14, 2010
- Thought Leader Perspective: Dr. Robert Kyle On Treating Multiple Myeloma
- Celgene Plans To Seek Approval Of Revlimid As An Initial Treatment For Multiple Myeloma
- M-CSF May Act As Powerful Prognostic Factor For Multiple Myeloma
- Papayas, Papain and Multiple Myeloma: A Potential Adjunct Therapy That Requires Further Evaluation
- FDA Approves Velcade’s Data Showing Survival Benefit In Newly Diagnosed Myeloma Patients
- Revlimid May Be More Effective Than Thalidomide In Newly Diagnosed Multiple Myeloma
- Elotuzumab In Combination With Revlimid And Dexamethasone Shows Encouraging Results In Multiple Myeloma (ASH 2009)
- Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite Preventative Medication (ASH 2009)
- ▼ March (7)
- ►2009 (269)
- ► December (17)
- Velcade-Thalidomide-Dexamethasone Treatment Is Promising For Newly Diagnosed Multiple Myeloma (ASH 2009)
- Addition Of Thalidomide To Induction Therapy Increases Response Rates In Younger And Older Multiple Myeloma Patients (ASH 2009)
- NPI-0052 Shows Promise In Relapsed/Refractory Multiple Myeloma (ASH 2009)
- Novel Therapeutic Agents May Reduce Kidney Impairment In Newly Diagnosed Myeloma Patients (ASH 2009)
- Preemptive Treatment Benefits High-Risk Smoldering Myeloma Patients, Study Finds (ASH 2009)
- Revlimid Maintenance Therapy Significantly Extends Disease-Free Survival
- Zolinza Combination Treatments Offer Benefit For Multiple Myeloma Patients (ASH 2009)
- Perifosine Combination Therapy Is Promising For Relapsed And Refractory Multiple Myeloma (ASH 2009)
- Revlimid May Set “New Standard” For Treating Newly Diagnosed Multiple Myeloma In Elderly Patients (ASH 2009)
- Tanespimycin-Velcade Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
- Survival Greater Than 10 Years In Multiple Myeloma Is Related To Longer Treatment Duration (ASH 2009)
- Beacon NewsFlashes - December 8, 2009
- Velcade-Dexamethasone Combination Regimen Increases Survival In Newly Diagnosed High Risk Myeloma Patients (ASH 2009)
- Carfilzomib Is Effective For Multiple Myeloma – Part 2: Treatment Of Specific Patient Groups (ASH 2009)
- Carfilzomib Is Effective For Multiple Myeloma – Part 1: As A Single Agent Or In A Combination Therapy (ASH 2009)
- Beacon NewsFlashes - December 3, 2009
- Velcade-Melphalan-Prednisone-Thalidomide (VMPT) Treatment Is Highly Active In Elderly Myeloma Patients (ASH 2009)
- ► November (15)
- Velcade-Torisel Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
- Serum Albumin Levels Indicate Severity Of Multiple Myeloma
- New Velcade Combination Therapy Effective For Newly Diagnosed Myeloma Patients (ASH 2009)
- Treatment Trends For Multiple Myeloma – Part 3: Options For Elderly Multiple Myeloma Patients
- Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)
- Beacon NewsFlashes – November 23, 2009
- Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
- Myeloma Research To Be Presented At The American Society of Hematology’s 51st Annual Meeting (ASH 2009)
- Vitamin C Inhibits Anti-Myeloma Activity Of Velcade
- Beacon NewsFlashes – November 13, 2009
- Treatment Trends For Multiple Myeloma – Part 2: Allogeneic Stem Cell Transplants
- The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
- Beacon NewsFlashes – November 6, 2009
- Lawsuit Filed To Overturn Ban On Payment For Bone Marrow Donations
- Treatment Trends For Multiple Myeloma – Part 1: Autologous Stem Cell Transplants
- ► October (19)
- Beacon NewsFlashes – October 30, 2009
- Velcade-Doxil-Dexamethasone Combination Treatment Is Highly Effective In Newly Diagnosed Multiple Myeloma Patients
- Thalidomide Improves Outcome Of Double Stem Cell Transplants In Younger Myeloma Patients
- Study Shows Higher Survival With Revlimid And Low-Dose Dexamethasone Than Revlimid And High-Dose Dexamethasone In Multiple Myeloma Patients
- Retreatment With Velcade As A Treatment Option For Relapsed Myeloma Patients
- Phase 2 Clinical Trial Offers Positive Results For A Steroid-Free Multiple Myeloma Treatment
- Beacon NewsFlashes – October 23, 2009
- Study Shows Benefits Of Vesselplasty In The Treatment Of Spinal Fractures
- New Recommendations Issued On Stem Cell Collection And Treatment With Revlimid, Thalidomide, And Velcade
- Multiple Myeloma Study Finds “Complete Response” Is Generally Correlated With Survival
- Myeloma Patients Are At Increased Risk For Blood Clots, Particularly Patients Using Revlimid Or Thalidomide
- Beacon NewFlashes - October 15, 2009
- Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
- New Directory Could Assist In Myeloma Treatment
- Beacon NewsFlashes – October 8, 2009
- Carfilzomib Is Highly Active In Relapsed Myeloma Patients
- Immune System Cells Protect Myeloma Cancer Cells, Study Finds
- TIMP-1 Biomarker Predicts Myeloma Progression And Survival
- Beacon NewsFlashes – October 2, 2009
- ► September (19)
- Taking Vitamin D And Calcium Supplements Together May Prevent Cancer
- New Drug Enters Phase 2 Clinical Trial For Stem Cell Collection For Blood Cancer Patients
- Second Dose Of Aloxi Further Reduces Chemotherapy-Induced Nausea In Cancer Patients
- New Study Highlights Myeloma Treatment Infection Risks
- Beacon NewsFlashes – September 23, 2009
- Study On Myeloma Diagnosis Techniques Favors Newer Imaging Methods
- Phase 3 Trial Indicates Denosumab Delays Skeletal Related Events In Cancer Patients
- Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
- Study Supports Use Of Kyphoplasty For Multiple Myeloma Patients
- Beacon NewsFlashes – September 16, 2009
- Swine Flu Vaccinations Recommended For Multiple Myeloma Patients
- Beacon NewsFlashes – September 12, 2009
- Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
- Multiple Myeloma Conferences To Be Held In Hawaii, Arizona, Canada, And Greece
- FDA To Review Velcade-Melphalan-Prednisone Regimen
- Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients
- Scientists Find A Protein That Causes Resistance To Velcade Treatment
- Macrophages May Contribute To Survival Of Multiple Myeloma Cells
- Beacon NewsFlashes – September 1, 2009
- ► August (17)
- Personal Perspective: Engineer With Myeloma Finds Hope Through Cancer Support Group And Blogs
- Beacon NewsFlashes – August 27, 2009
- Pathologic Fractures In Bisphosphonate-Treated Patients Not Indicative Of Myeloma Progression
- Personal Perspective: The Adventures Of Cancer Girl
- Eradicating H. pylori Infection Not Linked To MGUS Regression
- Beacon NewsFlashes – August 20, 2009
- Phase 1 Clinical Trial Studies Velcade And Zolinza In Myeloma Patients
- Kidney Failure In Multiple Myeloma Patients - Part 4: Hemodialysis
- Beacon NewsFlashes - August 14, 2009
- Skipped Bone Marrow Exams Give False Positives In Multiple Myeloma Clinical Trials
- Multiple Myeloma Vaccine Shows Promise In Mice
- High Incidence Of Multiple Myeloma In World Trade Center Responders
- Research Shows Velcade’s Possible Mechanism of Action
- Shortage of Clinical Trial Participants Hinders War On Cancer
- Beacon NewsFlashes – August 6, 2009
- Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
- Beacon NewsFlashes - August 3, 2009
- ► July (20)
- Study Shows Toxicity Of Second Transplant For Myeloma Patients
- Clinical Trials Start For A Pre-Transplant Treatment
- Researchers Sequence Full Multiple Myeloma Tumor Genome
- Beacon NewsFlashes – July 28, 2009
- Multiple Myeloma Patients’ Relatives Are Twice As Likely To Have MGUS
- Dr. Sagar Lonial Provides Insight Into High-Risk Myeloma
- Vitamin D Deficiency May Cause Skeletal Complications In Multiple Myeloma Patients
- Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
- Anti-DKK1 Antibody As New Treatment For Myeloma Bone Disease
- Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
- Beacon NewsFlashes – July 21, 2009
- Kidney Failure In Multiple Myeloma Patients – Part 3: Time and Care Commitments
- Dental Exams Recommended Before Bisphosphonate Therapy
- Kidney Failure In Multiple Myeloma Patients - Part 2: Treatment
- Beacon NewsFlashes -- July 14, 2009
- Quality Of Life Warrants More Consideration In Multiple Myeloma Treatment Recommendations
- Study Examines Quality Of Life After Stem Cell Transplantation
- Beacon NewsFlashes – July 8, 2009
- Vegetarians Less Likely To Develop Multiple Myeloma
- Revlimid As Initial Myeloma Therapy Inhibits Stem Cell Collection
- ► June (17)
- Beacon NewsFlashes — June 30, 2009
- Kidney Failure In Multiple Myeloma Patients - Part 1: Overview
- XRCC5 Gene Variants Associated With Greater Blood Clot Risk During Thalidomide Treatment
- Stem Cell Transplants May Improve Kidney Function of Myeloma Patients
- Beacon NewsFlashes -- June 24, 2009
- U.K. Finalizes Revlimid Therapy Guidelines
- Canadian Authorities Confiscating Thalidomide At Border
- Velcade Plus Dexamethasone Produces Robust, Yet Short-Lived, Response In Myeloma Patients
- Beacon NewsFlashes - June 15, 2009
- Revlimid Boosts Immune System Of Some Myeloma Patients
- Beacon NewsFlashes - June 9, 2009
- Study Shows Acute Kidney Failure Can Be Reversed By Velcade-Dexamethasone-Doxorubicin In Multiple Myeloma
- Total Therapy Emerges As Prospect For Multiple Myeloma Cure
- Myeloma Precursor MGUS Linked To Pesticide Use
- Beacon NewsFlashes – June 3, 2009
- Expert Panel Recommends European Approval Of Mozobil
- Study Examines Romidepsin-Velcade Combination Treatment In Myeloma Patients (ASCO 2009)
- ► May (23)
- ONJ As A Prognostic Factor In Myeloma Patients Treated With Zometa (ASCO 2009)
- Beacon NewsFlashes - May 29, 2009
- Nexavar Shows No Effect In Phase 2 Study (ASCO 2009)
- MMRF Announces Research Collaboration With The Broad Institute
- Clinical Trial Shows Ginger Reduces Nausea (ASCO 2009)
- New Hemodialysis Procedure Improves Health Of Multiple Myeloma Patients
- IGF-1: An Important Myeloma Growth Factor
- Trial Investigates Effects Of Tanespimycin-Velcade Combination Treatment (ASCO 2009)
- Autologous Stem Cell Transplant Therapy With Velcade-Revlimid Or Velcade-Thalomid in New Multiple Myeloma Patients (ASCO 2009)
- Phase 3 Study Shows High Response Rates For Four-Drug Combination (ASCO 2009)
- Beacon NewsFlashes - May 18, 2009
- Formaldehyde Exposure Linked To Increased Risk Of Multiple Myeloma
- ASCO 2009 - 45th Meeting Of The American Society Of Clinical Oncology Only Two Weeks Away
- Myeloma Patients In Canada Smuggle Low-Priced Thalidomide
- Beacon NewsFlashes – May 13, 2009
- Mozobil With Neupogen Increases Stem Cell Harvest Efficiency
- Iowa Firefighters And Police Officers To Benefit From Cancer Bill
- Durie-Salmon Staging System And International Staging System Compared In Patients After ASCT
- Socioeconomic Standing May Affect Survival For Swedish Myeloma Patients
- Beacon NewsFlashes – May 9, 2009
- Current Use Of Velcade In Newly Diagnosed Myeloma Patients
- Study Projects Rising Cancer Rates In The United States
- New Hampshire Legislature Approves Medical Marijuana Bill
- ► April (29)
- Study Finds Lack Of Evidence For Link Between Firefighting And Cancer
- Beacon NewsFlashes — April 28, 2009
- The Access To Cancer Trials Act Of 2009 Brought Before Congress
- Beacon NewsFlashes — April 27, 2009
- NICE Recommends Revlimid For Multiple Myeloma Patients In U.K.
- Melphalan-Prednisone Survival Rates Higher Than Thalidomide-Dexamethasone In Elderly
- Study Measures Effects Of Novel Drugs On Myeloma Patients With Chromosomal Abnormalities
- Beacon NewsFlashes – April 22, 2009
- Long-Term Outcome Of Combination Auto/Allo Stem Cell Transplant Treatment Reported
- Beacon NewsFlashes – April 20, 2009
- Beacon NewsFlashes – April 17, 2009
- New Revlimid Warning For Patients With Impaired Kidney Function
- Gene Identification Could Lead To Better Treatment Options For Multiple Myeloma
- High-Risk Myeloma Patients Show Overall Lower Progression-Free Survival With Revlimid-Dexamethosone Therapy
- Thalidomide Plus Prednisone Shown To Improve Survival After ASCT
- Beacon NewsFlashes – April 13, 2009
- Beacon NewsFlashes – April 10, 2009
- IMW 2009 - Physicians Debate "Cure Versus Control" Of Myeloma
- IMW 2009 – Physicians Discuss Induction Therapy For Non-Transplant Candidates
- IMW 2009 - Elotuzumab And Panobinostat Clinical Trials With Velcade
- CMS Decides To Cover PET Scans For Myeloma Patients
- Addition Of Second Drug Could Dramatically Improve Velcade Response
- Beacon NewsFlashes – April 7, 2009
- Tools For Diagnosing Multiple Myeloma / Part 4: Specialized Studies
- Growth In Off-Label Drug Use Slows
- Blood Cancers Forum Focuses On Importance Of Clinical Trials
- IMW 2009 – Physicians Discuss Upfront And Induction Therapy For Transplant Candidates
- Beacon NewsFlashes – April 1, 2009
- Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 2: Medicare-Approved Compendia
- ► March (31)
- New Gene Implicated In Multiple Myeloma And Other Cancers
- Kennedy Renews War On Cancer
- The MMRF Marathon And Half Marathon Program Seeks Runners
- Beacon NewsFlashes – March 29, 2008
- Beacon NewsFlashes - March 27, 2009
- Genetic Blood Tests Could Soon Identify Multiple Myeloma And Other Disorders
- Beacon NewsFlashes – March 25, 2009
- Tools For Diagnosing Multiple Myeloma / Part 3: Prognostic Evaluation
- Beacon NewsFlashes – March 23, 2009
- Beacon NewsFlashes – March 21, 2009
- Beacon NewsFlashes – March 20, 2009
- Scotland Expected To Improve Patient Access To New Cancer Therapies
- Beacon NewsFlashes - March 16, 2009
- IMW 2009 - Physicians Discuss New Drugs For Relapsed/Refractory Patients
- Beacon NewsFlashes - March 14, 2009
- Tools For Diagnosing Multiple Myeloma / Part 2: End-Organ Damage Evaluation
- New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
- Current Information On Response Criteria For Multiple Myeloma
- IMW 2009 - Physicians Discuss Symptom Management Strategies
- Beacon NewsFlashes - March 10, 2009
- Managing The Side Effects Of Revlimid And Velcade
- Beacon NewsFlashes – March 9, 2009
- Current Information On Risk Stratification In Multiple Myeloma
- New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
- Beacon NewsFlashes - March 6, 2009
- IMW 2009 - Waldenstrom's Award Goes To IMF Co-Founder And Chairman
- Blood Disorder MGUS Precedes Most Cases Of Multiple Myeloma
- The MMRF Awards $1 Million For Promising Early-Stage Drug Development
- Beacon NewsFlashes – March 2, 2009
- IMW 2009 – Consensus On Risk Stratification In Multiple Myeloma
- Beacon NewsFlashes - March 1, 2009
- ► February (32)
- Current Information On Staging Multiple Myeloma
- New Myeloma Drugs Target Different Mechanisms Of Action: Cell Surface Receptors
- Canadian Survey Highlights Myeloma Awareness And Access To Treatment
- Beacon NewsFlashes - February 24, 2009
- IMW 2009 - Physicians Offer Standardized Guidelines For Diagnosing Suspected Multiple Myeloma
- Radiation Not Linked To MGUS Progression To Multiple Myeloma
- Beacon NewsFlashes - February 23, 2009
- IMW 2009 - Doctors Clarify Standards For Clinical Trial Reporting
- Physicians Perform First Bone Marrow Transplant At Public Hospital In West Bengal, India
- Health Care-Associated MRSA In Decline
- XII International Myeloma Workshop Begins Next Week
- Clarifications And Updates In Diagnosis Criteria Of Multiple Myeloma
- Tools For Diagnosing Multiple Myeloma / Part 1: Diagnostic Evaluation
- Beacon NewsFlashes - February 18, 2009
- Bill Helps Oregon Firefighters Get Cancer Coverage
- Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 1
- MMRF And LLS Grant $500,000 For Study Of The Multiple Myeloma Stem Cell
- The American Society Of Clinical Oncology Provides A Financial Guide To Cancer Care
- Long-Term Survival Estimates Increase For Young Multiple Myeloma Patients
- Researchers Identify Novel Tumor Feeding Mechanism
- Beacon NewsFlashes - February 11, 2009
- Beacon NewsFlashes - February 11, 2009
- Leukemia & Lymphoma Society And Women’s Running Magazine Join Forces To Launch New Women’s Half Marathon
- Regulations And The Rising Cost Of Cancer Drugs
- MMRF Is The Official Charity Of The Rite Aid Cleveland 5K
- Beacon NewsFlashes - February 6, 2009
- Green Tea Blocks Effectiveness Of Velcade Treatment
- Beacon NewsFlashes - February 4, 2009
- Study Finds No Link Between Hair Dyes And Myeloma
- Beacon NewsFlashes – February 2, 2009
- Deal Brings Revlimid To U.K. Myeloma Patients
- Beacon NewsFlashes - February 1, 2009
- ► January (30)
- Preventive Measures Can Reduce Osteonecrosis Of The Jaw In Patients Taking Zometa
- Fruits And Vegetables Do Not Decrease Risk of Multiple Myeloma
- Beacon NewsFlashes – January 28, 2008
- FJC Awards $1 Million Grant To Institute For Myeloma And Bone Cancer Research
- Blood Cancers The Subject Of Seminar At University Of Chicago Medical Center
- Beacon NewsFlashes – January 26, 2009
- Radiation Therapy, Vertebroplasty, And Kyphoplasty: Three Treatments For Myeloma Bone Disease
- Scientists Develop Serum Immunoglobulin Free Light Chain Assay For Early Myeloma Diagnosis
- Chemical Used In Rubber Synthesis Increases Risk Of Myeloma
- New Drug for Preventing Nausea and Vomiting During Chemotherapy
- Beacon NewsFlashes – January 21, 2009
- MMRF Meeting Discusses Prognosis And Treatments For Myeloma Patients
- Multiple Myeloma Treatment Approaches And Objectives
- Phase 3 Zolinza-Velcade Trial Opening Soon
- New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
- Beacon NewsFlashes - January 19, 2009
- Thalomide Approved For First-Line Treatments In Scotland
- Treatment In Elderly Multiple Myeloma Patients
- Tandem Autologous Stem Cell Transplantation Compared To Single Autologous Stem Cell Transplantation
- Managing Steroid-Related Side Effects In Myeloma Patients
- MMRF Meeting Discusses Racial Disparities In Multiple Myeloma
- Novel Therapies For Myeloma Bone Disease
- Beacon NewsFlashes – January 13, 2009
- Bisphosphonate Treatment For Myeloma Bone Disease
- Beacon NewsFlashes – January 9, 2009
- Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
- U.K. To Expand Access To Drugs For Terminally Sick
- Anti-Cancer Drug Zolinza Shows Potential In Myeloma
- Beacon NewsFlashes – January 5, 2009
- Osteoporosis Drug Increases Risk Of Esophageal Cancer And Jaw Disease
- ► December (17)
- ►2008 (65)
- ► December (34)
- Beacon NewsFlashes - December 30, 2008
- Cancer Drugs To Cost More Under Medicare Plans
- Leading Oncologists Present Clinical Research Advances in 2008
- Clinical Trials Begin For New Form Of Radiotherapy
- Skeletal Imaging For Bone Lesions In Multiple Myeloma Patients
- ASH 2008 - New Induction Therapy for Elderly Patients
- ASH 2008 - High Response Rate for Revlimid-Velcade-Dexamethasone Treatment in Phase 2 Studies
- Diana Krall To Host Fundraiser Benefiting Blood Cancer Patients
- FDA Approves Mozobil For Myeloma Patients Preparing For Stem Cell Transplants
- Treatment In Young Multiple Myeloma Patients
- ASH 2008 – Results Of Tandem Stem Cell Treatment For Newly Diagnosed Myeloma Patients
- ASH 2008 - Ongoing Phase 2 Clinical Trials For Carfilzomib Show Promising Results
- ASH 2008 - Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
- ASH 2008 – Trial Results Compare Multiple Myeloma Transplantation Procedures
- ASH 2008 – Venous Thrombotic Events In Newly Diagnosed Myeloma Patients Decrease Overall Survival
- Beacon NewsFlashes - December 16, 2008
- Impact of PET Scans Consistent Across All Types of Cancer
- ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
- Beacon NewsFlashes - December 12, 2008
- ASH 2008 – Clinical Trial Update for Velcade-Thalidomide-Dexamethasone With Autologous Stem Cell Transplantation In Newly Diagnosed Myeloma Patients
- Multiple Myeloma Research Consortium Announces Center Of The Year
- ASH 2008 – Updated Velcade-Melphalan-Prednisone Trial Results For Newly Diagnosed Myeloma Patients
- Deep Vein Thrombosis Risk Higher In Multiple Myeloma
- ASH 2008 - VDD Initial Treatment More Effective Than TD Initial Treatment
- ASH 2008 - Actimid-Dexamethasone Combination Highly Effective In Treating Relapsed And Refractory Multiple Myeloma
- ASH 2008 - Scientists Reveal Promising Four-Drug Regimen For Newly-Diagnosed Myeloma Patients
- Phase 3 Trials Of Hsp90 Inhibitors In Cancer Patients Underway
- Outpatient Stem Cell Transplant For Multiple Myeloma
- New Therapies Show Promise For Multiple Myeloma Treatment
- Beacon NewsFlashes - December 5, 2008
- Multiple Myeloma Survivors Honored At 2008 ASH Meeting
- 50th Annual Meeting Of The American Society Of Hematology Only Days Away
- Beacon NewsFlashes – December 2, 2008
- Physicians Discuss Past Progress And Future Goals In Treating Multiple Myeloma
- ► November (30)
- Holiday Party In Las Vegas To Benefit The Leukemia & Lymphoma Society
- Parade In New Zealand To Benefit Families Living With Multiple Myeloma
- U.S. Cancer Incidence And Mortality Rates Fall For The First Time
- Revlimid Combination Effective Against Relapsed And Refractory Myeloma
- Beacon NewsFlashes - November 23, 2008
- Increased Risk Of Blood Clotting Reported In Patients Treated With Avastin
- IMF Continues Support Of Peter Boyle Memorial Fund
- Long-Term Exposure To Benzene Appears To Increase Risk Of Multiple Myeloma
- New Technique Shows Improved Detection Of Myeloma Tumor Cells After Treatment
- IMF Announces New Global Research Partnership To Study Multiple Myeloma Biomarkers
- Beacon NewsFlashes - November 17, 2008
- Treatment With Folic Acid And B Vitamins Has Little Effect On Multiple Myeloma Risk Among Women
- Beacon NewsFlashes - November 14, 2008
- Link Between Gene Variation And Myeloma Survival
- ImmunoCellular Therapeutics Presents Data Showing Immune Response On Cancer Stem Cells
- Occupation And Chemical Exposure Linked To Multiple Myeloma
- African-Americans Still At Higher Risk Of Developing Multiple Myeloma
- Beacon NewsFlashes - November 11, 2008
- CIGNA, Leukemia & Lymphoma Society Promote Financial Aid Program
- Beacon NewsFlashes - November 7, 2008
- International Myeloma Foundation Calls For Patient Access To Newest Myeloma Treatments
- Beacon NewsFlashes – November 6, 2008
- Antibody Treatment In Mice Shows Antitumor Activity
- Prolexys Pharmaceuticals Raises $20 Million to Further Work on Anti-tumor Molecule
- Immune System Cells Show Promise As Myeloma Therapy
- FDA Approves Cephalon's Treanda for Second Cancer Indication
- MMRF Raises Over $1.5 Million In Annual Fall Gala
- Incidence Of Multiple Myeloma In Women May Correlate With Height, Not Obesity
- England And Wales May Halt Funding For Revlimid
- Scientist Receives $720,000 Grant To Research New Myeloma Drug Targets
- ► October (1)
- ► December (34)